Patents by Inventor Claudio Cavazza

Claudio Cavazza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050100583
    Abstract: A food selected from the group comprising milk and dairy products derived from milk, comprising a carnitine in an effective amount to stimulate, through the natural fatty acid metabolic processes that take place in a consumer of said food, the synthesis of polyunsaturated fatty acids from the saturated fatty acids originally contained in the food.
    Type: Application
    Filed: December 13, 2004
    Publication date: May 12, 2005
    Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20050026846
    Abstract: The co-ordinated use of an alkanoyl L-carnitine (e.g. propionyl L-carnitine) and a statine (e.g. simvastatin) is disclosed for treating pathologies brought about by an altered lipid metabolism, wherein by coordinated use both the substantially contemporaneous co-administration of the two active ingredients and the administration of a combination composition comprising a mixture of the two active ingredients, is meant.
    Type: Application
    Filed: August 30, 2004
    Publication date: February 3, 2005
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20050020538
    Abstract: A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterizing active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners.
    Type: Application
    Filed: June 9, 2004
    Publication date: January 27, 2005
    Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 6814972
    Abstract: A composition is disclosed which is suitable for the prevention and/or treatment of vasculopathic, cardiac, central and peripheral cerebral disturbances and for the prevention of learning disorders or disorders related to ageing, as well as for coping with increased energy requirements, and which may take the form of a dietary supplement or an actual medicine in its own right, containing the following as its characterising active ingredients: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts; and (b) coenzyme Q10.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: November 9, 2004
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20040209906
    Abstract: The use of ketanserin in combination with L-carnitine, some alkanoyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed for the treatment of CRPS.
    Type: Application
    Filed: April 28, 2003
    Publication date: October 21, 2004
    Applicant: Sigma-Tau industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Cavazza, Menotti Calvani
  • Patent number: 6780851
    Abstract: A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterising active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: August 24, 2004
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 6761898
    Abstract: The present invention relates to a composition, which contains L-carnitine or alkanoyl-L-carnitine, and a glucosaminoglycan or a constituent thereof, suitable for the prevention of articular disorders and for the therapeutic treatment of articular diseases.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: July 13, 2004
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20040110836
    Abstract: The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
    Type: Application
    Filed: December 1, 2003
    Publication date: June 10, 2004
    Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20040057994
    Abstract: A composition is disclosed which is suitable for the prevention and treatment of kidney dysfunctions and diseases and which can therefore take the form of a food supplement or of an actual medicinal drug comprising a combination of acetyl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts.
    Type: Application
    Filed: September 23, 2003
    Publication date: March 25, 2004
    Applicant: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 6696492
    Abstract: Patients suffering from diabetic and/or dysmetabolic nephropathy are treated with L-carnitine or its alkanoyl derivatives.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: February 24, 2004
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Cavazza, Giovanni Valentini
  • Patent number: 6696493
    Abstract: The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: February 24, 2004
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 6653349
    Abstract: A composition is disclosed which is suitable for the prevention and treatment of kidney dysfunctions and diseases and which can therefore take the form of a food supplement or of an actual medicinal drug, comprising a combination of acetyl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: November 25, 2003
    Assignee: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20030206895
    Abstract: A composition is disclosed which comprises as characterizing active ingredients propionyl L-carnitine and a flavonoid, typically quercetin or its 3-rutinoside, rutin, for the prevention and/or therapeutic treatment of various alterations and pathological states induced by free radicals and by thrombotic or atherosclerotic abnormalities, that may take the form of a dietary supplement, dietetic support or of an actual medicine.
    Type: Application
    Filed: June 4, 2003
    Publication date: November 6, 2003
    Applicant: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 6641849
    Abstract: A composition is disclosed suitable for the prevention and/or treatment of circulatory disorders at both peripheral and cerebral level, and which can therefore take the form of a dietary supplement, a dietetic support or of an actual medicine, comprising as characterizing active ingredients: (a) a carnitine selected from the group consisting of acetyl L-carnitine and propionyl L-carnitine or a pharmacologically acceptable salt thereof or mixtures thereof; and (b) an extract of Ginkgo biloba or one or more of the ginkgolides isolated from Ginkgo biloba or mixtures thereof.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: November 4, 2003
    Assignee: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20030199535
    Abstract: A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said peripheral neuropathies, an effective amount of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof. In case of prevention, acetyl L-carnitine is administered to a subject, in view of the need of a treatment with an anticancer agent, immediately before or immediately after surgical removal of the tumor, but in any case before the administration of the anticancer agent. Acetyl L-carnitine can enhance the supportive effect of physiological NGF during chemotherapy-induced neuropathy, thus avoiding the problem of the local and general side effects of the exogenous administration of NGF which are a major problem of this neuroprotective strategy.
    Type: Application
    Filed: November 13, 2002
    Publication date: October 23, 2003
    Inventors: Claudio Cavazza, Claudio Pisano, Loredana Vesci
  • Patent number: 6610699
    Abstract: Alkanoyl L-carnitines of the formula: where R is hydrogen or a C2-8 alkanoyl group and X− is an anion of a pharmaceutically acceptable salt, are used in conjunction with anticancer agents such as taxol or bleomycin to improve the therapeutic index and reduce side effects typical of anticancer chemotherapy.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: August 26, 2003
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Cavazza, Claudio Pisano, Loredana Vesci
  • Patent number: 6602512
    Abstract: A composition is disclosed suitable for the prevention and/or treatment of muscular energetic deficiencies and states of asthenia for enhancing sport performances and for the treatment of states of heart fatigue, that may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients a combination of L-carnitine and/or at least one alkanoyl L-carnitine and creatinol-phosphate.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: August 5, 2003
    Assignee: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20030144354
    Abstract: A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.
    Type: Application
    Filed: November 6, 2002
    Publication date: July 31, 2003
    Inventor: Claudio Cavazza
  • Patent number: 6565876
    Abstract: A composition is disclosed suitable for the prevention and/or treatment of cardiovascular and neurocerebral disorders, tissue anoxic forms, muscular energy deficits, inflammatory-type abnormalities, alterations of blood coagulation such as thrombosis, and tissue proliferation forms, that may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; and (b) an inositol phosphate, particularly the inositol hexaphosphate (IP6).
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: May 20, 2003
    Assignee: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20030059418
    Abstract: A composition is disclosed which is suitable for the prevention and/or treatment of vasculopathic, cardiac, central and peripheral cerebral disturbances and for the prevention of learning disorders or disorders related to ageing, as well as for coping with increased energy requirements, and which may take the form of a dietary supplement or an actual medicine in its own right, containing the following as its characterising active ingredients: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts; and (b) coenzyme Q10.
    Type: Application
    Filed: October 22, 2002
    Publication date: March 27, 2003
    Inventor: Claudio Cavazza